Odulimomab, also known by its CAS number 159445-64-4, is a monoclonal antibody that targets the CD3 receptor on T cells, which plays a crucial role in the immune response. This therapeutic agent is primarily investigated for its potential in treating various autoimmune diseases and certain types of cancer by modulating T cell activity. Odulimomab functions by binding to the CD3 complex, thereby influencing T cell activation and proliferation. Its mechanism of action can lead to a reduction in the autoimmune response or enhance anti-tumor immunity, depending on the context of its use. The substance is characterized by its specificity for the CD3 receptor, which is a hallmark of T cell function, and its ability to alter immune responses. As a biologic drug, odulimomab is produced through recombinant DNA technology, ensuring a high degree of purity and specificity. Ongoing research continues to explore its efficacy, safety, and potential applications in clinical settings.

Odulimomab

159445-64-4: Odulimomab, also known by its CAS number 159445-64-4, is a monoclonal antibody that targets the CD3 receptor on T cells, which plays a crucial role in the immune response. This therapeutic agent is primarily investigated for its potential in treating various autoimmune diseases and certain types of cancer by modulating T cell activity. Odulimomab functions by binding to the CD3 complex, thereby influencing T cell activation and proliferation. Its mechanism of action can lead to a reduction in the autoimmune response or enhance anti-tumor immunity, depending on the context of its use. The substance is characterized by its specificity for the CD3 receptor, which is a hallmark of T cell function, and its ability to alter immune responses. As a biologic drug, odulimomab is produced through recombinant DNA technology, ensuring a high degree of purity and specificity. Ongoing research continues to explore its efficacy, safety, and potential applications in clinical settings.

<p>Odulimomab: anti-LFA-1 antibody, inhibits T cell growth, protects against ischemic injury, used in transplant rejection research.</p>

<p>Anti-CD11a mouse monoclonal antibody; potential for preventing transplant rejection</p>

CAS 159445-64-4

Odulimomab

Odulimomab

Ref: TM-T77106

Odulimomab

Ref: 3D-CLA1108